Boston Scientific Corp (MIL:1BSX)
€ 85.5 0 (0%) Market Cap: 126.98 Bil Enterprise Value: 135.61 Bil PE Ratio: 74.26 PB Ratio: 6.39 GF Score: 56/100

Boston Scientific Corp at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 01:00PM GMT
Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Good morning, everyone, and welcome to our next session here at the UBS global health care conference.

I'm Matt Taylor, and I'm the U.S. medical supplies and devices analyst hosting sessions here in the medtech track and really excited to have with us management from Boston Scientific.

So we've got a number of leaders here from the peripheral and oncology group, including Jeff Mirviss, EVP and Global President of Peripheral Interventions, President of Interventional Oncology; Cat Jennings, who's VP of Vascular Marketing, New Business Development, and GM for Varithena; and also have Susie Lisa, the VP of Investor Relations and (inaudible) as well. So we're going to focus on peripheral and oncology, but we can ask Susie and Lauren some questions about broader BSC. Or they'll keep me in line if we're trying to get these folks off track and give us all the secrets, but I just want to start by saying thanks a lot for joining us today and really appreciate you taking the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot